Clinical Pharmacokinetics

, Volume 47, Issue 5, pp 285–295 | Cite as

Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate

Review Article

Abstract

The direct thrombin inhibitor dabigatran etexilate is currently in phase III of development for the prophylaxis and treatment of thromboembolic disorders, with three trials completed in primary venous thromboembolism (VTE) prevention. Dabigatran etexilate is an orally administered prodrug, which is rapidly absorbed and converted to the active form, dabigatran. Dabigatran has been shown to specifically and reversibly inhibit thrombin, the key enzyme in the coagulation cascade. Studies in healthy volunteers and in patients undergoing orthopaedic surgery have indicated that dabigatran has a predictable pharmacokinetic/pharmacodynamic profile, allowing for a fixed-dose regimen. Peak plasma concentrations of dabigatran are reached approximately 2 hours after oral administration in healthy volunteers, with no unexpected accumulation of drug concentrations upon multiple dosing. Excretion is predominantly via the renal route as unchanged drug. Dabigatran is not metabolized by cytochrome P450 isoenzymes. The small differences in dabigatran pharmacokinetics associated with age and gender are attributed to variations in renal function. Additional studies have shown that the pharmacokinetic/pharmacodynamic profile of dabigatran is consistent across a range of patient populations, with no effect of moderate hepatic impairment being observed. Drug-drug interactions are not observed with concomitant administration of atorvastatin, diclofenac or digoxin. The pharmacodynamic profile of dabigatran demonstrates effective anticoagulation combined with a low risk of bleeding. Further phase III studies are ongoing, including acute VTE treatment and stroke prevention in atrial fibrillation; the results obtained so far show that dabigatran etexilate is well tolerated and effective in the treatment and prevention of thromboembolic events.

References

  1. 1.
    Husmann M, Barton M. Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease. Expert Opin Investig Drugs 2007 May; 16(5): 563–7PubMedCrossRefGoogle Scholar
  2. 2.
    Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997 May 24; 349(9064): 1498–504PubMedCrossRefGoogle Scholar
  3. 3.
    Hyers TM. Management of venous thromboembolism: past, present, and future. Arch Intern Med 2003 Apr 14; 163(7): 759–68PubMedCrossRefGoogle Scholar
  4. 4.
    Hirsh J. Heparin. N Engl J Med 1991 May 30; 324(22): 1565–74PubMedCrossRefGoogle Scholar
  5. 5.
    Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004 Sep; 126(3 Suppl.): 188S–203SPubMedCrossRefGoogle Scholar
  6. 6.
    Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002 Sep 9; 162(16): 1833–40PubMedCrossRefGoogle Scholar
  7. 7.
    Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med 2003 Aug; 3(3): 221–30PubMedCrossRefGoogle Scholar
  8. 8.
    Oldenburg J, Watzka M, Rost S, et al. VKORC1: molecular target of coumarins. J Thromb Haemost 2007; 5 Suppl. 1: 1–6PubMedCrossRefGoogle Scholar
  9. 9.
    Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005 Sep 8; 353(10): 1028–40PubMedCrossRefGoogle Scholar
  10. 10.
    Hauptmann J, Sturzebecher J. Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thromb Res 1999 Mar 1; 93(5): 203–41PubMedCrossRefGoogle Scholar
  11. 11.
    Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 2003 Jul 15; 109 Suppl. 1: S9–15PubMedCrossRefGoogle Scholar
  12. 12.
    Wienen W, Stassen JM, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007 Jul; 98(1): 155–62PubMedGoogle Scholar
  13. 13.
    Wolzt M, Sarich TS, Eriksson UG. Pharmacokinetics and pharmacodynamics of ximelagatran. Semin Vasc Med 2005 Aug; 5(3): 245–53PubMedCrossRefGoogle Scholar
  14. 14.
    Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. Epub 2007 May 15Google Scholar
  15. 15.
    AstraZeneca. AstraZeneca decides to withdraw Exanta [press release]. London: AstraZeneca, 2006 Feb 14Google Scholar
  16. 16.
    Hauel NH, Nar H, Priepke H, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002 Apr 25; 45(9): 1757–66PubMedCrossRefGoogle Scholar
  17. 17.
    Markwardt F. Hirudin as alternative anticoagulant: an historical review. Semin Thromb Hemost 2002 Oct; 28(5): 405–14PubMedCrossRefGoogle Scholar
  18. 18.
    Stassen JM, Rathgen K, Zimmermann R, et al. Pharmacodynamics of the oral direct thrombin inhibitor BIBR 953 [abstract]. J Thromb Haemost 2001; 86 Suppl.: OC160Google Scholar
  19. 19.
    Wienen W, Stassen JM, Priepke H, et al. Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis. J Thromb Haemost 2007 Jun; 5(6): 1237–42PubMedCrossRefGoogle Scholar
  20. 20.
    Wienen W, Nar H, Ries UJ, et al. Antithrombotic effects of the direct thrombin inhibitor BIBR-953ZW and its orally active prodrug BIBR-1048MS in a model of venous thrombosis in rabbits [abstract]. J Thromb Haemost 2001; 86 Suppl.: OC853Google Scholar
  21. 21.
    Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005 May; 45(5): 555–63PubMedCrossRefGoogle Scholar
  22. 22.
    Stangier J, Stähle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of direct thrombin inhibitor dabigatran in elderly healthy subjects [abstract no. P2207]. J Thromb Haemost 2005; 3(Suppl. 1): P2207Google Scholar
  23. 23.
    Stangier J, Rathgen K, Gansser D, et al. Pharmacokinetics of BIBR 953 ZW, a novel low molecular weight direct thrombin inhibitor in healthy volunteers [abstract]. J Thromb Haemost 2001; 86 Suppl.: OC2347Google Scholar
  24. 24.
    Stangier J, Rathgen K, Stähle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007 Sep; 64(3): 292–303PubMedCrossRefGoogle Scholar
  25. 25.
    Stangier J, Rathgen K, Stähle H, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate in subjects with moderate hepatic impairment [abstract no. P-W-673; online]. XXIst Congress of the International Society of Thrombosis and Haemostasis; 2007 Jul 6–12; Geneva. Available from URL: http://isth2007.abstractsondemand.com/ [Accessed 2008 Feb 29]Google Scholar
  26. 26.
    Stangier J, Stähle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47(1): 47–59PubMedCrossRefGoogle Scholar
  27. 27.
    Stangier J, Nehmiz G, Liesenfeld KH, et al. Pharmacokinetics of BIBR 953 ZW, the active form of the oral direct thrombin inhibitor BIBR 1048, in patients undergoing hip replacement [abstract]. J Thromb Haemost 2003; 1 Suppl 1: P1916Google Scholar
  28. 28.
    Troconiz IF, Tillmann C, Liesenfeld KH, et al. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacol 2007 Mar; 47(3): 371–82PubMedCrossRefGoogle Scholar
  29. 29.
    Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004 Sep; 2(9): 1573–80PubMedCrossRefGoogle Scholar
  30. 30.
    Cullberg M, Eriksson UG, Wahlander K, et al. Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clin Pharmacol Ther 2005 Apr; 77(4): 279–90PubMedCrossRefGoogle Scholar
  31. 31.
    Garnett C, Liesenfeld KH, Tillmann C, et al. Modelling and clinical trial simulation in drug development: the effect of renal impairment on the exposure-response relationship of a direct thrombin inhibitor, BIBR 1048, in hip replacement patients [poster]. Annual Meeting of the American Association of Pharmaceutical Scientists; 2003 Nov, Salt Lake City (UT)Google Scholar
  32. 32.
    Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008 Feb; 36(2): 386–99PubMedCrossRefGoogle Scholar
  33. 33.
    Stangier J, Stähle H, Rathgen K. Effect of food and pantoprazole on the bioavailability of the direct thrombin inhibitor dabigatran in healthy subjects [abstract no. P1612]. J Thromb Haemost 2005; 3(Suppl. 1): P1612Google Scholar
  34. 34.
    Rathgen K, Stangier J, Stähle H. Bioavailability of BIBR 953 after 150mg BIBR 1048 (oral prodrug of BIBR 953) administered as HPMC capsule relative to a gelatine capsule, ands bioavailability of the HPMC capsule under the influence of food in healthy subjects [Boehringer Ingelheim clinical study report]. Biberach (Germany): Boehringer Ingelheim Pharma GmbH and Co KG, 2004Google Scholar
  35. 35.
    Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005 Jan; 3(1): 103–11PubMedCrossRefGoogle Scholar
  36. 36.
    Stangier J, Stähle H, Rathgen K, et al. Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and atorvastatin has little impact on the pharmacokinetics and pharmacodynamics of either drug [abstract no. P-W-671; online]. XXIst Congress of the International Society of Thrombosis and Haemostasis; 2007 Jul 6–12; Geneva. Available from URL: http://isth2007.abstractsondemand.com/ [Accessed 2008 Feb 29]Google Scholar
  37. 37.
    Stangier J, Stähle H, Rathgen K, et al. Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and diclofenac has little impact on the pharmacokinetics of either drug [abstract no. P-T-677; online]. XXIst Congress of the International Society of Thrombosis and Haemostasis; 2007 Jul 6–12; Geneva. Available from URL: http://isth2007.abstractsondemand.com/ [Accessed 2008 Feb 29]Google Scholar
  38. 38.
    Stangier J, Stähle H, Rathgen K, et al. No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin [abstract no. P-W-672; online]. XXIst Congress of the International Society of Thrombosis and Haemostasis; 2007 Jul 6–12; Geneva. Available from URL: http://isth2007.abstractsondemand.com/ [Accessed 2008 Feb 29]Google Scholar
  39. 39.
    Caprini JA, Hwang E, Hantel S, et al. The oral direct thrombin inhibitor, dabigatran etexilate, is effective and safe for prevention of major venous thromboembolism following major orthopedic surgery [abstract no. O-W-050; online]. XXIst Congress of the International Society of Thrombosis and Haemostasis; 2007 Jul 6–12; Geneva. Available from URL: http://isth2007.abstractsondemand.com/ [Accessed 2008 Feb 29]Google Scholar
  40. 40.
    Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement [abstract no. O-W-049; online]. XXIst Congress of the International Society of Thrombosis and Haemostasis; 2007 Jul 6–12; Geneva. Available from URL: http://isth2007.abstractsondemand.com/ [Accessed 2008 Feb 29]Google Scholar
  41. 41.
    Friedman RJ, Caprini JA, Comp PC, et al. Dabigatran etexilate versus enoxaparin in preventing venous thromboembolism following total knee arthroplasty [abstract no. O-W-051; online]. XXIst Congress of the International Society of Thrombosis and Haemostasis; 2007 Jul 6–12; Geneva. Available from URL: http://isth2007.abstractsondemand.com/ [Accessed 2008 Feb 29]Google Scholar
  42. 42.
    Samama MM, LeFlem L, Guinet C, et al. Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants. J Thromb Haemost 2007; 5: 2554–6PubMedCrossRefGoogle Scholar
  43. 43.
    Samama MM, Le Flem L, Guinet C, et al. Three different patterns of calibrated automated thrombogram obtained with hirudin, melagatran, dabigatran, argatroban, fondaparinux and danaparoid [abstract no. P-W-644; online]. XXIst Congress of the International Society of Thrombosis and Haemostasis; 2007 Jul 6–12; Geneva. Available from URL: http://isth2007.abstractsondemand.com/ [Accessed 2008 Feb 29]Google Scholar
  44. 44.
    Liesenfeld KH, Schafer HG, Troconiz IF, et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006 Nov; 62(5): 527–37PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Boehringer Ingelheim Pharma GmbH and Co. KGBiberachGermany
  2. 2.Department of Drug Metabolism and PharmacokineticsBoehringer Ingelheim Pharma GmbH and Co. KG, Birkendorfer StrasseBiberach an der RissGermany

Personalised recommendations